Adjuvant endocrine therapy for the surgeon: Options, side effects, and their management

Annals of Surgical Oncology

Volumn 20, Issue 10, 2013, Pages 3188-3193

  Connor, Carol ^a   Attai, Deanna ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Center for Breast Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYTOCHROME P450 2D6; ESTROGEN; EXEMESTANE; GOSERELIN; LETROZOLE; LEUPRORELIN; PLACEBO; PROGESTERONE; RALOXIFENE; TAMOXIFEN; TOREMIFENE; VENLAFAXINE;

ABLATION THERAPY; ACUPUNCTURE; ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DISEASE FREE SURVIVAL; DRUG SUBSTITUTION; EMOTIONAL DISORDER; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EYE DISEASE; FATIGUE; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HEADACHE; HOT FLUSH; HUMAN; LIBIDO DISORDER; MENOPAUSAL SYNDROME; META ANALYSIS (TOPIC); MONOTHERAPY; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; TUMOR ABLATION; VAGINA DISCHARGE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDOCRINE SYSTEM; FEMALE; HUMANS; PROGNOSIS;

EID: 84883778743     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3177-1     Document Type: Article

References (41)

1. Fabian CJ. The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract. 2007;61(12):2051-63.
2. International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol. 2004;15:1749-59.
3. Fisher B, Jeong J-H, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N. Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr. 2001;30:62-6.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378: 771-84.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
6. Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-16.
7. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet. 1896;II(104-7):162-5.
8. Griggs J, Somerfield M, Anderson H, et al. American Society of Clinical Oncology endorsement of the cancer care ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J Clin Oncol. 2011;29(29):3939-42.
9. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;360:1711-23.
10. Swain S, Jeong J-H, Geyer C, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010; 362(22):2053-65.
11. Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793-802.
12. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigator. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135-41.
13. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747-57.
14. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455-62.
15. van de Velde C, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377:321-31.
16. The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76.
17. Higgins M, Liedke P, Goss P. Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1-97 trial. Crit Rev Oncol Hematol. 2013;86:23-32.
18. Goss P. National Cancer Institute of Canada Clinical Trials Group MA-27 trial reported at the San Antonio Breast Cancer Symposium, December 2012.
19. Fontein DBY, Seynaeve C, Hadji P, et al. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis. J Clin Oncol. 2013 31(18):2257-64. doi: 10.1200/JCO.2012.45.3068.
20. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784-96.
21. Fallowfield LJ, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life in postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol. 2004;22:4261-71.
22. Fallowfield LJ, Kilburn LS, Langridge C, Snowdon CF, Bliss JM, Coombes RC on behalf of the IES Trial Steering Committee. Long-term assessment of quality of life in the intergroup exemestane study: 5 years post-randomisation. Br J Cancer. 2012;106:1062-7.
23. Garreau JR, DeLaMelena T, Walts D, Karamlou K, Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am J Surg. 2006;192:496-8.
24. Blaha P, Exner R, DalBorgo A, et al. Is endocrine therapy really pleasant? considerations about the long-term use of antihormonal therapy and its benefit/side effect ratio. Breast Care. 2009;4:155-61.
25. Hershman DL, Kushi L, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120-8.
26. Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, Buist DSM. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract. 2012;8:e149-57.
27. Friese C, Pini TM, Li Y, et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat. 2013;138:931-9.
28. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91:1829-46.
29. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-84.
30. Mouridsen HT. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin. 2006;22:1609-21.
31. Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107:167-80.
32. Michaëllson K, Melhus H, Warensjö Lemming E, Wolk A, Byberg L. Long-term calcium intake and rates of all cause and cardiovascular mortality: community-based prospective longitudinal cohort study. BMJ. 2013;346:f228.
33. Greenlee H, Crew KD, Shao T, et al. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer. 2013;21:1077-87.
34. Crew KD, Capodice JL, Greenlee H, et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010;28:1154-60.
35. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen at 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a Randomised Trial. Lancet 2013;381:805-16.
36. Breast Cancer Social Media Community http://www.bcsmcommunity.org.
37. Walker EM, Rodriguez AI, Kohn B, et al. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol. 2010;28:638-40.
38. Hind D, Wyld L, Beverley C, Reed M. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Libr. 2008, 3.
39. Hughes K, Schnaper L, Bellon J, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382-7.
40. NCCN Guidelines. Breast Cancer. Version 3.2013.
41. Pemmaraju N, Munsell MF, Hortobagyi GN, Giordano SH. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side effects. Ann Oncol. 2011. doi: 10.1093/annonc/mdr459.